globalhealthcare, Author at GLOBAL HEALTHCARE MAGAZINE

Covid boosters work against omicron, without a variant-specific third dose

December 17, 2021: -White House chief medical advisor Dr. Anthony Fauci said Wednesday that currently available booster shots work against the omicron variant of Covid-19 and do not need to be adjusted to fight the new, highly contagious strain of the virus at this time.

Tianjin launches mass Covid testing after omicron exposure

January 13, 2022: -On Wednesday, the Chinese city of Tianjin began a new round of testing of its 14 million residents to block the omicron variant, as financial analysts warned of the growing economic costs on China of curbs to extinguish clusters of infections.

Changing Healthcare Market-Owkin Raises $25 million

July 7, 2020: The trailblazer startup from New York has a plan to have a collaborative research and development model that works among the pharmaceutical companies and the hospitals and no actual data is shared.

CDC has warned lawmakers that delta variant is as contagious

August 02, 2021: -On Thursday, the CDC warned House lawmakers that the new delta variant sweeping across the country is as contagious as chickenpox, has a longer transmission window than the original strain of Covid-19, and may make older people sicker, even if they’ve been fully vaccinated, according to a copy of the document reviewed by CNBC and authenticated by the U.S. agency.

Booster shot protects against omicron variant in Israeli study

December 14, 2021: -On Sunday, Israeli researchers said they found that a three-shot course of the Pfizer-BioNTech Covid-19 vaccine provided huge protection against the new Omicron variant.

BioNTech plans to produce vaccines in Singapore

May 12, 2021: -On Monday, BioNTech announced it would set up its Southeast Asia headquarters in Singapore and build a manufacturing facility in the city-state to produce its messenger RNA vaccines and different medicines to treat infectious diseases and cancer.

AstraZeneca to work on COVID-19 vaccine with Russia’s Sputnik V

AstraZeneca to work on COVID-19 vaccine with Russia’s Sputnik V December 13, 2020 British pharmaceutical giant AstraZeneca said Friday it would soon start work with Russia’s Gamaleya Institute to investigate whether their two coronavirus vaccine candidates could be successfully combined. It comes after the developers of the Sputnik V Covid-19 vaccine approached AstraZeneca via Twitter last month to ask if they should try combining both to boost vaccine efficacy. “Being able to combine different COVID-19 vaccines may help improve protection and improve vaccine accessibility. This is why it is important to explore different vaccine combinations to help make immunization programs more flexible, by allowing physicians greater choice at the time of administering vaccines,” AstraZeneca said in a statement. AstraZeneca’s Covid-19 vaccine, produced in collaboration with the University of Oxford, is one of several seeking to secure approval from medicine regulators amid rising hopes that a mass vaccination campaign could help end the pandemic. To date, more than 69 million people have contracted the coronavirus worldwide, with 1.58 million related deaths, according to data compiled by Johns Hopkins University. “We welcome the beginning of this new stage of cooperation between vaccine producers. We are determined to develop this partnership in the future and to start joint production after the new vaccine demonstrates its efficacy in the course of clinical trials,” Dmitriev said. Top News